Guide

Medicare and Tirzepatide in 2026: The Bridge, and Who It Leaves Out

The Medicare GLP-1 Bridge began on 1 July 2026 and caps eligible Part D enrollees at about $50 a month for Wegovy, Zepbound or Foundayo. Prior authorisation is required a

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

The Medicare GLP-1 Bridge began on 1 July 2026 and caps eligible Part D enrollees at about $50 a month for Wegovy, Zepbound or Foundayo. Prior authorisation is required and can take weeks. Manufacturer savings cards remain barred on Medicare by federal law.

Answer last reviewed: 2026-08-03

What does the comparison actually show?

Medicare routes to tirzepatide
Route	Cost	Condition
Bridge, if eligible	~$50/month	Part D enrolment, prior authorisation, BMI criteria
Manufacturer savings card	Barred	Federal anti-kickback law. No workaround
Cash compounded	$186 flat	No insurance involved, so Medicare status is irrelevant
Cash brand vials	$299–$449	Same

Why cash routes stay open on Medicare

The savings-card prohibition applies to drugs paid for by a federal programme. Paying out of pocket does not involve Medicare at all, so cash routes are available regardless of your Medicare status.

That is the practical option for anyone who does not qualify for the Bridge or cannot wait out prior authorisation — $186 a month captured, against $50 if the Bridge comes through.

The Bridge is a demonstration with an end date, and the CMS Balance Model is scheduled for January 2027 as the permanent successor. Both are policy rather than settled entitlement.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What does each route cost?

Tirzepatide by route, monthly and annual
Route	Monthly	Twelve months	Evidence
Commercial cover plus savings card	$25	$300	Provider-reported
Medicare GLP-1 Bridge	$50	$600	Reported
Compounded, 12-month, flat	$186	$2,232	Captured at source
Compounded, month-to-month, flat	$215	$2,580	Captured at source
Brand Zepbound, LillyDirect vials	$299–$449	$4,788	Captured at source
Brand Zepbound, retail pens	~$1,060	~$12,720	Third-party claim

Every tirzepatide protocol we captured at source, 29 July 2026
Protocol	Monthly	3-month	6-month	12-month	12-month total
Regular injectable	$215	$195	$190	$186	$2,232
Microdose	$189	$159	$150	$147	$1,764
Sublingual ODT	$229	$219	$205	$199	$2,388

Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Does Medicare cover tirzepatide?

Through the GLP-1 Bridge from 1 July 2026, eligible Part D enrollees pay about $50 a month with prior authorisation.

Can I use a savings card on Medicare?

No. Federal law bars manufacturer copay cards on any Medicare-paid drug, with no workaround.

What if I do not qualify for the Bridge?

Cash routes remain available regardless of Medicare status, because paying out of pocket does not involve the programme.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Medicare and Tirzepatide in 2026: The Bridge, and Who It Leaves Out.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/medicare-tirzepatide-coverage-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.